Allergan reaches 100 million milestone for Botox

24 Apr 2019

Global pharmaceutical company Allergan has manufactured the 100 millionth vial of botulinum toxin type A Botox, which the company has said is a ‘significant milestone in the history of the brand’.

Allergan explains that it is currently used in 97 countries for aesthetic and therapeutic use in 35 different indications and has been subject to 148 clinical trials. According to the company, it is continuing to collaborate with researchers, scientists and academic bodies to find new uses for botulinum toxin. Mitchell Brin, senior vice president global drug development and chief scientific officer said, “After 30 years of studying this drug, we have a large safety database and we are now moving into other disorders that I would say two decades ago I would have not had anticipated going into.” 


Log-in to post a comment